References
- Laprise C, de Pokomandy A, Baril JG, et al. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. Clin Infect Dis. 2013;57:1489–1496.
- Greub G, Cozzi-Lepri A, Ledergerber B, et al. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS. 2002;16:1967–1969.
- Assoumou L, Descamps D, Yerly S, et al. Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study. J Antimicrob Chemother. 2013;68:1400–1405.
- Delaugerre C, Gallien S, Flandre P, et al. Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients. PloS One. 2012;7:e36673.
- Gallien S, Delaugerre C, Charreau I, et al. Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia. AIDS. 2011;25:665–669.
- Li JZ, Gallien S, Do TD, et al. Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia. Antimicrob Agents Chemother. 2012;56:5998–6000.
- Doyle T, Smith C, Vitiello P, et al. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2012;54:724–732.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Section C11. Available online at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed
- Graf T, Pinto AR. The increasing prevalence of HIV-1 subtype C in Southern Brazil and its dispersion through the continent. Virology. 2013;435:170–178.
- Neogi U, Haggblom A, Santacatterina M, et al. Temporal trends in the Swedish HIV-1 epidemic: increase in non-B subtypes and recombinant forms over three decades. PloS One. 2014;9:e99390.
- Dolling D, Hué S, Delpech V, et al. The increasing genetic diversity of HIV-1 in the UK, 2002-2010. AIDS. 2014;28:773–780.
- Siemieniuk RA, Beckthold B, Gill MJ. Increasing HIV subtype diversity and its clinical implications in a sentinel North American population. Can J Infect Dis Med Microbiol. 2013;24:69–73.
- Lindstrom A, Albert J. A simple and sensitive 'in-house' method for determining genotypic drug resistance in HIV-1. J Virol Methods. 2003;107:45–51.
- Steegen K, Demecheleer E, De Cabooter N, et al. A sensitive in-house RT-PCR genotyping system for combined detection of plasma HIV-1 and assessment of drug resistance. J Virol Methods. 2006;133:137–145.
- Elbeik T, Hoo BS, Campodonico ME, et al. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy. J Hum Virol. 2001;4:317–328.
- Waters L, Mandalia S, Asboe D. Successful use of genotypic resistance testing in HIV-1-infected individuals with detectable viraemia between 50 and 1000 copies/ml. AIDS. 2006;20:778–779.
- Mackie N, Dustan S, McClure MO, et al. Detection of HIV-1 antiretroviral resistance from patients with persistently low but detectable viraemia. J Virol Methods. 2004;119:73–78.
- Mitsuya Y, Winters MA, Fessel WJ, et al. HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mL. J Acquir Immune Defic Syndr. 2006;43:56–59.